Akouos

40 articles with Akouos

• Akouos to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference

  11/22/2021

  Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), today announced that Manny Simons, Ph.D., M.B.A., co-founder, president, and chief executive officer of Akouos, participated in a pre-recorded fireside chat that will be published today as part of the Piper Sandler 33rd Annual Healthcare Conference.

• Akouos Reports Third Quarter 2021 Financial Results and Provides Business Highlights

  11/12/2021

  Akouos, Inc., a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, reports financial results for the third quarter ended September 30, 2021, and provides business highlights.

• 

  BioSpace Movers & Shakers, Nov. 5

  11/5/2021

  Biopharma and life sciences organizations strengthen their leadership teams and board with these Movers & Shakers.

• Akouos Appoints Stacy Price as Chief Technical Officer

  11/1/2021

  Akouos, Inc. today announced the appointment of Stacy Price as chief technical officer.

• Akouos to Present at Jefferies Gene Therapy/Editing Summit

  10/20/2021

  Akouos, Inc. today announced that Manny Simons, Ph.D., M.B.A., co-founder, president, and chief executive officer of Akouos, will participate in a presentation at the Jefferies Gene Therapy/Editing Summit on Wednesday, October 27 at 9:30 a.m. EDT.

• Akouos to Present at Upcoming September 2021 Virtual Investor Conferences

  9/7/2021

  Akouos, Inc., a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, announced that Manny Simons, Ph.D., M.B.A., co-founder, president, and chief executive officer of Akouos, will present at two upcoming virtual investor conferences in September

• Akouos Reports Second Quarter 2021 Financial Results and Provides Business Highlights

  8/12/2021

  Akouos, Inc. today reports financial results for the second quarter ended June 30, 2021 and provides business highlights.

• Akouos Announces European Commission Designation of AK-OTOF for the Treatment of Otoferlin Gene-Mediated Hearing Loss as an Orphan Drug

  8/11/2021

  Akouos, Inc., a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, announced that the European Medicines Agency Committee for Orphan Medicinal Products issued a positive opinion on the company’s application for orphan drug designation for AK-OTOF, a gene therapy intended for the treatment of otoferlin gene-mediated hearing loss.

• Akouos to Present at Upcoming August 2021 Virtual Investor Conferences

  8/4/2021

  Akouos, Inc., a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, announced that Manny Simons, Ph.D., M.B.A., co-founder, president, and chief executive officer of Akouos, will present at two upcoming virtual investor conferences in August:

• 

  BioSpace Movers & Shakers, May 14

  5/14/2021

  Biopharma and life sciences companies strengthen their leadership teams and boards with Movers & Shakers.

• Akouos Reports First Quarter 2021 Financial Results and Provides Business Updates

  5/13/2021

  AK-OTOF granted both Orphan Drug Designation and Rare Pediatric Disease Designation by FDA and is on track for planned IND submission in first half of 2022

• 

  Cutting-Edge Tech: Highlights from the American Society of Gene & Cell Therapy

  5/11/2021

  The 24th Annual meeting of the American Society of Gene & Cell Therapy presents cutting-edge work in the booming area of gene and cell therapy. Here’s a look at a few of the highlights.

• Akouos Presents Nonclinical Data Supporting Future Clinical Development of AK-OTOF and AK-antiVEGF at the American Society of Gene and Cell Therapy 24th Annual Meeting

  5/11/2021

  - Intracochlear delivery of a dual AAVAnc80 vector encoding human otoferlin results in full-length protein expression in inner hair cells of non-human primates and in durable protein expression sufficient for sustained restoration of auditory function in Otof knockout mice

• Akouos to Present at Bank of America 2021 Virtual Healthcare Conference

  5/7/2021

  Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that Manny Simons, Ph.D., M.B.A., co-founder, president, and chief executive officer of Akouos, will participate in a fireside chat at the Bank of America 2021 Virtual Healthcare Conference on Wednesday, May 12 at 2:00 p.m. EDT.

• Akouos Appoints Dr. Kathy Reape as Chief Development Officer

  5/7/2021

  Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced the appointment of Dr. Kathy Reape as chief development officer.

• Akouos to Present Nonclinical Data from AK-OTOF and AK-antiVEGF Programs at the American Society of Gene and Cell Therapy 24th Annual Meeting

  4/27/2021

  Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that new nonclinical data will be presented at the American Society of Gene and Cell Therapy 24th Annual Meeting,

• Akouos Receives Orphan Drug and Rare Pediatric Disease Designations for AK-OTOF for the Treatment of Otoferlin Gene-Mediated Hearing Loss

  4/13/2021

  Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that the U.S. Food and Drug Administration (FDA) has granted both Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) for AK-OTOF, a gene therapy intended for the treatment of otoferlin gene-mediated hearing loss.

• Akouos to Present at 20th Annual Needham Virtual Healthcare Conference

  4/8/2021

  Akouos, Inc., a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, announced that Manny Simons, Ph.D., founder, president, and CEO of Akouos, will participate in a fireside chat at the 20th Annual Needham Virtual Healthcare Conference on Wednesday, April 14 at 4:30 p.m. ET.

• Akouos Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Highlights

  3/29/2021

  - In 2020, continued to advance genetic medicine pipeline with execution of IND-enabling studies for AK-OTOF and general alignment with FDA on the path to a 2022 IND submission for AK-antiVEGF - Raised approximately $349 million in gross proceeds, which is expected to fund operations for at least two years

• Akouos to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference

  11/23/2020

  Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that Manny Simons, Ph.D., M.B.A., CEO, President and co-founder, participated in a pre-recorded fireside chat that will be published today as part of the Piper Sandler 32 nd Annual Virtual Healthcare Conference taking place December 1 to 3, 2020. Th